PRVA

Privia Health Group Inc

Add to Watchlist

Advanced Chart

20.330

-0.25(-1.215%)1D

Overview
Forecast
Valuation
Earnings

Line

Candle

YTD

High

20.660

Open

20.530

VWAP

20.29

Vol

1.27M

Mkt Cap

2.49B

Low

20.060

Amount

25.74M

EV/EBITDA(TTM)

58.42

Total Shares

119.32M

2.19B

EV/OCF(TTM)

23.80

P/S(TTM)

1.38

Privia Health Group, Inc. is a technology-driven, national physician-enablement company. The Company collaborates with medical groups, health plans and health systems. It enhances physician practices, improves patient experiences and doctors for delivering care in both in-person and virtual care settings. Its Privia Platform is powered by the Privia Technology Solution, an end-to-end, cloud-based technology solution that integrates both Privia-developed and third-party applications into an interface and workflow that manages all aspects of its Privia Providers provision of healthcare services. Privia Platform optimizes provider workflow across the full continuum of reimbursement arrangements. The Company provides management services to each Medical Group though a local management services organization, which provides Medical Groups with access to value-based care (VBC) opportunities either directly or through Privia-owned accountable care organizations.

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2026Q1

FY2025Q4

FY2025Q3

536.87M

+11.83%

502.06M

+8.93%

490.97M

+12.11%

Estimates Revision

The market is revising Upward the revenue expectations for Privia Health Group, Inc. (PRVA) for FY2025, with the revenue forecasts being adjusted by 0.18% over the past three months. During the same period, the stock price has changed by -18.87%.

Revenue Estimates for FY2025

Revise Upward

+0.18%

In Past 3 Month

Stock Price

Go Down

-18.87%

In Past 3 Month

7 Analyst Rating

45.60% Upside

Wall Street analysts forecast PRVA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for PRVA is 29.60 USD with a low forecast of 24.00 USD and a high forecast of 32.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

6 Buy

1 Hold

0 Sell

Strong Buy

45.60% Upside

Current: 20.330

Low

24.00

Averages

29.60

High

32.00

45.60% Upside

Current: 20.330

Low

24.00

Averages

29.60

High

32.00

JPMorgan

Lisa Gill

maintain

$29 -> $32

2025-05-28

Reason

JPMorgan

Lisa Gill

Price Target

$29 -> $32

2025-05-28

maintain

Reason

JPMorgan analyst Lisa Gill raised the firm's price target on Privia Health to $32 from $29 and keeps an Overweight rating on the shares. The firm updated the company's model.

Barclays

Equal Weight

maintain

$23 -> $24

2025-05-27

Reason

Barclays

Price Target

$23 -> $24

2025-05-27

maintain

Equal Weight

Reason

Barclays raised the firm's price target on Privia Health to $24 from $23 and keeps an Equal Weight rating on the shares post the Q1 report. The company showed "steady progress" with modest outperformance in the fee-for-service business, well-controlled costs, and a clear path to 20% EBITDA growth in 2026, the analyst tells investors in a research note.

Baird

Michael Ha

Buy

Maintains

$24 → $26

2025-04-15

Reason

Baird

Michael Ha

Price Target

$24 → $26

2025-04-15

Maintains

Buy

Reason

Baird analyst Michael Ha raised the firm's price target on Privia Health to $26 from $24 and keeps an Outperform rating on the shares. The firm sees minimal incremental buyers of stocks in the managed care and healthcare facilities group until the policy overhang clears. Baird does not not expect guidance raises as it believes companies will maintain 2025 "conservatism and cushion" given potential Part D and macro headwinds that may evolve later this year.

Needham

Matthew Sheerin

Strong Buy

Reiterates

$30

2025-04-10

Reason

Needham

Matthew Sheerin

Price Target

$30

2025-04-10

Reiterates

Strong Buy

Reason

Truist Securities

Jailendra Singh

Strong Buy

Maintains

$27 → $28

2025-04-10

Reason

Truist Securities

Jailendra Singh

Price Target

$27 → $28

2025-04-10

Maintains

Strong Buy

Reason

Truist lowered the firm's price target on Privia Health to $28 from $30 and keeps a Buy rating on the shares as part of a broader research note previewing Q1 results in the Healthcare IT industry. The industry is typically shielded from macro uncertainty, but tariffs and concerns around an economic slowdown have created broader market uncertainty, which is never good for a high-beta highly volatile group like HCIT/Digital Health/Payviders, the analyst tells investors in a research note. Truist adds that while HCIT companies may not be directly exposed to new tariffs, several of these companies serve end markets - hospitals, pharma, etc. - which are likely to see either some direct impact on their supply chain costs or could decide to slow down on their investments.

Barclays

Andrew Mok

Hold

Maintains

$21 → $23

2025-04-10

Reason

Barclays

Andrew Mok

Price Target

$21 → $23

2025-04-10

Maintains

Hold

Reason

Barclays raised the firm's price target on Privia Health to $23 from $21 and keeps an Equal Weight rating on the shares as part of a Q1 earnings preview for the managed care space.

See All Ratings

Valuation Metrics

The current forward P/E ratio for Privia Health Group Inc (PRVA.O) is 75.77, compared to its 5-year average forward P/E of 43.75. For a more detailed relative valuation and DCF analysis to assess Privia Health Group Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

43.75

Current PE

75.77

Overvalued PE

356.20

Undervalued PE

-268.69

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

Fair

5Y Average EV/EBITDA

38.38

Current EV/EBITDA

18.26

Overvalued EV/EBITDA

59.52

Undervalued EV/EBITDA

17.24

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

Fair

5Y Average PS

2.00

Current PS

1.21

Overvalued PS

2.91

Undervalued PS

1.10